Necmettin Erbakan University
erbakan.edu.trLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
189
Active
48
Phase 3
0
Total enrollment
18,384
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Adenosine deaminase acting on RNA1 | — | — | — | — | — | 1 |
Next readouts
- 2026-07-01
Top conditions
- Pain10
- Periodontal Diseases9
- Anxiety6
- Periodontitis6
- Breast Cancer4
- Satisfaction4
- Gingival Recession4
- Nursing Students3
Frequently asked questions about Necmettin Erbakan University
- How many clinical trials does Necmettin Erbakan University have on ClinicalTrials.gov?
- Necmettin Erbakan University is listed as the lead sponsor on 189 clinical trials in ClinicalTrials.gov, 48 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Necmettin Erbakan University's trials are in Phase 3?
- 0 of Necmettin Erbakan University's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Necmettin Erbakan University focus on?
- Necmettin Erbakan University's most-studied conditions on ClinicalTrials.gov are Pain, Periodontal Diseases, Anxiety, Periodontitis, Breast Cancer.
- When are Necmettin Erbakan University's next clinical trial readouts?
- Necmettin Erbakan University has 1 upcoming primary-completion readout tracked here; the soonest is “ADAR1 Expression Level in Rectal Cancer”, expected around 2026-07-01.